AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38脳BCMA脳CD3 Trispecific Antibody
AbbVie (NYSE: ABBV) has entered into an exclusive licensing agreement with IGI Therapeutics SA for ISB 2001, a first-in-class CD38脳BCMA脳CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, plus tiered, double-digit royalties on net sales.
ISB 2001 was developed using IGI's proprietary BEAT庐 protein platform and represents a new frontier in immuno-oncology by engaging multiple targets simultaneously.
AbbVie (NYSE: ABBV) ha stipulato un accordo di licenza esclusiva con IGI Therapeutics SA per ISB 2001, un anticorpo trispecifico CD38脳BCMA脳CD3 di prima classe attualmente in fase 1 di sperimentazione clinica per il mieloma multiplo recidivante/refrattario.
Secondo l'accordo, AbbVie ottiene i diritti esclusivi per sviluppare, produrre e commercializzare ISB 2001 in Nord America, Europa, Giappone e Grande Cina. IGI ricever脿 un pagamento iniziale di 700 milioni di dollari ed 猫 idonea a ricevere fino a 1,225 miliardi di dollari in pagamenti legati a milestone, oltre a royalties a doppia cifra su scala progressiva sulle vendite nette.
ISB 2001 猫 stato sviluppato utilizzando la piattaforma proteica proprietaria BEAT庐 di IGI e rappresenta una nuova frontiera nell'immuno-oncologia grazie al coinvolgimento simultaneo di pi霉 bersagli.
AbbVie (NYSE: ABBV) ha firmado un acuerdo de licencia exclusiva con IGI Therapeutics SA para ISB 2001, un anticuerpo trispec铆fico CD38脳BCMA脳CD3 de primera clase que actualmente se encuentra en ensayos cl铆nicos de fase 1 para mieloma m煤ltiple en reca铆da/refractario.
Seg煤n el acuerdo, AbbVie obtiene los derechos exclusivos para desarrollar, fabricar y comercializar ISB 2001 en Norteam茅rica, Europa, Jap贸n y Gran China. IGI recibir谩 un pago inicial de 700 millones de d贸lares y puede recibir hasta 1.225 millones de d贸lares en pagos por hitos, adem谩s de regal铆as escalonadas de dos d铆gitos sobre las ventas netas.
ISB 2001 fue desarrollado utilizando la plataforma proteica patentada BEAT庐 de IGI y representa una nueva frontera en la inmunooncolog铆a al dirigirse simult谩neamente a m煤ltiples objetivos.
AbbVie (NYSE: ABBV)電� IGI Therapeutics SA鞕� ISB 2001鞐� 雽�頃� 霃呾爯 霛检澊靹犾姢 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. ISB 2001鞚� 順勳灛 鞛皽/攵堨潙靹� 雼る皽靹� 瓿垬膦呾潉 雽�靸侅溂搿� 1靸� 鞛勳儊鞁滍棙 欷戩澑 斓滌磮鞚� CD38脳BCMA脳CD3 靷检韸轨澊 頃泊鞛呺媹雼�.
氤� 瓿勳暯鞐� 霐半澕 AbbVie電� 攵侂, 鞙犽熃, 鞚茧掣 氚� 雽�欷戧淡 歆�鞐棎靹� ISB 2001鞚� 臧滊皽, 鞝滌“ 氚� 靸侅梾頇旐暊 霃呾爯 甓岆Μ毳� 須嶋摑頃╇媹雼�. IGI電� 7鞏� 雼煬鞚� 靹犼笁旮�鞚� 氚涥碃, 斓滊寑 12鞏� 2,500毵� 雼煬鞚� 毵堨澕鞀ろ啢 歆�旮夑笀瓿� 靾滊Г於滌棎 霐半ジ 雼硠氤� 霊� 鞛愲靾� 搿滌棿韹半ゼ 氚涭潉 鞛愱博鞚� 鞛堨姷雼堧嫟.
ISB 2001鞚� IGI鞚� 霃呾瀽鞝侅澑 BEAT庐 雼氨歆� 頂岆灚韽检潉 靷毄頃� 臧滊皽霅橃棃鞙茧┌, 鞐煬 響滌爜鞚� 霃欖嫓鞐� 瓴儱頃橂姅 氅挫棴頃晹 攵勳暭鞚� 靸堧鞖� 歆�韽夓潉 鞐搓碃 鞛堨姷雼堧嫟.
AbbVie (NYSE: ABBV) a conclu un accord de licence exclusive avec IGI Therapeutics SA pour ISB 2001, un anticorps trispecifique CD38脳BCMA脳CD3 de premi猫re classe actuellement en essais cliniques de phase 1 pour le my茅lome multiple en rechute/r茅fractaire.
Dans le cadre de cet accord, AbbVie obtient les droits exclusifs de d茅velopper, fabriquer et commercialiser ISB 2001 en Am茅rique du Nord, en Europe, au Japon et en Grande Chine. IGI recevra un paiement initial de 700 millions de dollars et pourra percevoir jusqu'脿 1,225 milliard de dollars en paiements li茅s 脿 des jalons, ainsi que des redevances 茅chelonn茅es 脿 deux chiffres sur les ventes nettes.
ISB 2001 a 茅t茅 d茅velopp茅 gr芒ce 脿 la plateforme prot茅ique propri茅taire BEAT庐 d鈥橧GI et repr茅sente une nouvelle avanc茅e en immuno-oncologie en ciblant plusieurs cibles simultan茅ment.
AbbVie (NYSE: ABBV) hat eine exklusive Lizenzvereinbarung mit IGI Therapeutics SA f眉r ISB 2001 geschlossen, einen neuartigen trispezifischen Antik枚rper CD38脳BCMA脳CD3, der sich derzeit in Phase-1-Studien bei rezidivierendem/refrakt盲rem Multiplen Myelom befindet.
Im Rahmen der Vereinbarung erh盲lt AbbVie exklusive Rechte zur Entwicklung, Herstellung und Vermarktung von ISB 2001 in Nordamerika, Europa, Japan und Gro脽china. IGI erh盲lt eine Vorabzahlung von 700 Millionen US-Dollar und hat Anspruch auf bis zu 1,225 Milliarden US-Dollar an Meilensteinzahlungen sowie gestaffelte zweistellige Lizenzgeb眉hren auf den Nettoumsatz.
ISB 2001 wurde mit IGIs propriet盲rer BEAT庐 Proteinplattform entwickelt und stellt eine neue Dimension in der Immunonkologie dar, indem es mehrere Ziele gleichzeitig anspricht.
- Significant deal value with $700M upfront payment and potential $1.225B in milestone payments
- Access to novel trispecific antibody technology targeting multiple myeloma
- Expansion of AbbVie's oncology portfolio with first-in-class therapy
- Strategic entry into growing multispecific antibody market
- ISB 2001 still in early Phase 1 trials with uncertain clinical outcomes
- Substantial upfront investment required before proof of efficacy
Insights
AbbVie's $700M upfront deal for IGI's novel trispecific antibody strengthens its multiple myeloma pipeline with significant market potential.
This licensing agreement represents a substantial strategic investment by AbbVie to bolster its oncology portfolio, particularly in multiple myeloma where unmet needs persist despite recent therapeutic advances. The
ISB 2001's trispecific mechanism targeting CD38脳BCMA脳CD3 represents cutting-edge immuno-oncology science. By simultaneously engaging multiple targets, this approach aims to overcome resistance mechanisms that limit current therapies. The BEAT庐 protein platform that generated this candidate has distinguished itself with this first-in-class molecule currently in Phase 1 for relapsed/refractory multiple myeloma patients.
For AbbVie, this acquisition strategically complements their existing oncology franchise and addresses potential future competitive pressures from patent cliffs in other therapeutic areas. For IGI, retaining rights outside North America, Europe, Japan and Greater China while securing substantial milestone opportunities represents an impressive deal structure that validates their platform technology.
The valuation metrics鈥攑articularly the substantial upfront payment for an early-stage asset鈥攊ndicate exceptional confidence in the platform and preliminary data. Multiple myeloma remains a multi-billion dollar market with significant room for improved outcomes, making this a potentially transformative addition to AbbVie's pipeline with favorable risk-reward characteristics despite the early development stage.
- ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)
"Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously," said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress."
"ISB 2001 exemplifies the potential of our BEAT庐 protein platform to generate effective multispecifics that may overcome resistance and improve outcomes in hard-to-treat cancers," said Cyril Konto, M.D., President and CEO of IGI. "This agreement marks a defining milestone in IGI's scientific journey and reflects our team's deep commitment to delivering meaningful therapies for patients. Our partnership with AbbVie accelerates ISB 2001's path to patients and sharpens our focus on advancing the next generation of BEAT庐-enabled assets in oncology."
Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas 鈥� immunology, oncology, neuroscience, and eye care 鈥� and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at听www.abbvie.com. Follow @abbvie on听LinkedIn,听Facebook,听Instagram,听X (formerly Twitter), and听YouTube.
About听AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.
Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit .
About ISB听2001
ISB听2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells currently in Phase听1 for relapsed/refractory multiple myeloma. Developed using IGI's proprietary BEAT庐听protein platform, ISB听2001 was engineered with two distinct binders against myeloma-associated antigens to enhance avidity, even at low target expression levels, while aiming to improve safety over first-generation bispecific antibodies.听 Recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a Rapid Oral Presentation (), data from 35 patients demonstrated a sustained overall response rate (ORR) of
About the BEAT庐 Multispecific鈩� Platform
IGI's proprietary BEAT庐 platform goes beyond traditional bispecific antibody approaches, addressing key engineering bottlenecks that have historically limited large-scale bispecific production. By leveraging a proprietary common light chain library and TCR interface-based heavy chain pairing, BEAT庐 enables the development of next-generation immune cell engagers with strong therapeutic potential in oncology. Unlike many engineered formats, BEAT庐 mirrors the architecture of natural antibodies utilizing both light and heavy chains to enhance stability and function. Key attributes of the BEAT庐 platform include its multispecific versatility, enabling the design of antibodies that engage diverse immune cell types such as T cells, myeloid cells, and NK cells against multiple antigens. The platform also features optimized engineering through high-fidelity heavy chain pairing with a common light chain, allowing for precise Fc modulation and access to a broad structural design space. Additionally, BEAT庐 supports robust manufacturability, producing correctly assembled multispecific antibodies with favorable stability, extended half-lives, low immunogenicity and high titer yields through standardized process development and manufacturing operations.
About IGI听
IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in
AbbVie Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie Contacts: Media Sourojit (Jit) Bhowmick, Ph.D.
Liz Shea | IGI contact: 听 IGI Corporate Communications Team听 |
听
听
View original content to download multimedia:
SOURCE AbbVie
FAQ
What is the value of AbbVie's licensing agreement with IGI for ISB 2001?
What type of drug is ISB 2001 and what does it treat?
Which territories are included in AbbVie's licensing rights for ISB 2001?
What stage of development is ABBV's newly licensed drug ISB 2001?
How was ISB 2001 developed and what makes it unique?
